BioSpace News Archive

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full year 2020 financial results before the market opens on Thursday, March 18, 2021. Following the release, the Company will host a live conference call and webcast at 8:30 am EDT to discuss its financial results

OncoSynergy, Inc., a physician-founded oncology company committed to advancing therapeutics to address dire unmet medical needs, announced that the first patient was treated in the Company’s First-in-Human Phase 1 clinical trial evaluating OS2966 for the treatment of recurrent glioblastoma at Moffitt Cancer Center in Tampa, Florida.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority

Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of Jason Campagna , M.D., Ph.D. as Chief Medical Officer. Dr. Campagna brings more than 15 years of biotech and pharmaceutical experience to the Q32 Bio executive team

An analysis of adult human brain tissue reveals over 900 proteins tied to epilepsy. The brain disorder, estimated to afflict more than 3 million Americans, is mostly known for symptoms of hallucinations, dreamlike states, and uncontrolled, often disabling bodily seizures.

Gvoke® net sales of $20.2 million for full-year 2020 Continued Gvoke prescription growth – over 350% in 2020 Strong cash position of $133.8 million Conference call and webcast today at 8:30 a.m. ET

Partnership improves access to genetic counseling services when suspected hereditary cancer gene variant is identified through Foundation Medicine’s tumor testing

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ solutions as prescription medical treatments, today announced a partnership with youturn, the leader in evidence-based and therapist-led video content about substance use disorder, providing Clickotine®, a clinically validated, fully digital smoking cessation program, to youturn’s enterprise customers spanning nearly 5,000 members

– Primary and secondary endpoints were met, key exploratory endpoints supported clinical benefit in Phase 3 study of omidubicel in patients with hematologic malignancies; BLA submission anticipated in fourth quarter of 2021- — Omidubicel commercial preparation underway, including the creation of Gamida Cell Assist, to support potential launch —

The company is supporting vaccinations across 43 states and jurisdictions as part of the Federal Retail Pharmacy Program